#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Gut Microbiota in RA and OA
1-1	0-2	3.	_	_	_	_
1-2	3-6	Gut	abstract[1]	new[1]	_	_
1-3	7-17	Microbiota	abstract[1]	new[1]	_	_
1-4	18-20	in	abstract[1]	new[1]	_	_
1-5	21-23	RA	abstract[1]|organization	new[1]|new	coref	2-18
1-6	24-27	and	abstract[1]	new[1]	_	_
1-7	28-30	OA	abstract[1]|abstract	new[1]|new	coref	21-8

#Text=The hypothesis that not only oral but also intestinal microbiota can be associated with the development of RA is supported by many data . Zhang et al. published a case-control metagenome-wide association study ( MGWAS ) of the fecal , dental and salivary microbiomes of a cohort of treatment-naive and treated RA patients .
2-1	31-34	The	abstract[4]	new[4]	_	_
2-2	35-45	hypothesis	abstract[4]	new[4]	_	_
2-3	46-50	that	abstract[4]	new[4]	_	_
2-4	51-54	not	abstract[4]	new[4]	_	_
2-5	55-59	only	abstract[4]	new[4]	_	_
2-6	60-64	oral	abstract[4]	new[4]	_	_
2-7	65-68	but	abstract[4]	new[4]	_	_
2-8	69-73	also	abstract[4]	new[4]	_	_
2-9	74-84	intestinal	abstract[4]|abstract[5]	new[4]|new[5]	coref	4-31[0_5]
2-10	85-95	microbiota	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-11	96-99	can	_	_	_	_
2-12	100-102	be	_	_	_	_
2-13	103-113	associated	_	_	_	_
2-14	114-118	with	_	_	_	_
2-15	119-122	the	event[6]	new[6]	_	_
2-16	123-134	development	event[6]	new[6]	_	_
2-17	135-137	of	event[6]	new[6]	_	_
2-18	138-140	RA	event[6]|organization	new[6]|giv	coref	2-52
2-19	141-143	is	_	_	_	_
2-20	144-153	supported	_	_	_	_
2-21	154-156	by	_	_	_	_
2-22	157-161	many	abstract[8]	new[8]	_	_
2-23	162-166	data	abstract[8]	new[8]	_	_
2-24	167-168	.	_	_	_	_
2-25	169-174	Zhang	_	_	_	_
2-26	175-177	et	_	_	_	_
2-27	178-181	al.	_	_	_	_
2-28	182-191	published	_	_	_	_
2-29	192-193	a	abstract[10]	new[10]	appos	2-35[0_10]
2-30	194-206	case-control	abstract[10]	new[10]	_	_
2-31	207-222	metagenome-wide	abstract[10]	new[10]	_	_
2-32	223-234	association	organization|abstract[10]	new|new[10]	_	_
2-33	235-240	study	abstract[10]	new[10]	_	_
2-34	241-242	(	_	_	_	_
2-35	243-248	MGWAS	abstract	giv	coref	4-2[22_0]
2-36	249-250	)	_	_	_	_
2-37	251-253	of	_	_	_	_
2-38	254-257	the	substance[12]|abstract[13]	new[12]|new[13]	coref|coref|coref|coref	4-14[26_12]|4-14[27_13]|4-14[26_12]|4-14[27_13]
2-39	258-263	fecal	substance[12]|abstract[13]	new[12]|new[13]	_	_
2-40	264-265	,	abstract[13]	new[13]	_	_
2-41	266-272	dental	abstract[13]|object[14]	new[13]|new[14]	_	_
2-42	273-276	and	abstract[13]|object[14]	new[13]|new[14]	_	_
2-43	277-285	salivary	abstract[13]|object[14]	new[13]|new[14]	_	_
2-44	286-297	microbiomes	abstract[13]|object[14]	new[13]|new[14]	_	_
2-45	298-300	of	abstract[13]|object[14]	new[13]|new[14]	_	_
2-46	301-302	a	abstract[13]|object[14]|person[15]	new[13]|new[14]|new[15]	_	_
2-47	303-309	cohort	abstract[13]|object[14]|person[15]	new[13]|new[14]|new[15]	_	_
2-48	310-312	of	abstract[13]|object[14]|person[15]	new[13]|new[14]|new[15]	_	_
2-49	313-328	treatment-naive	abstract[13]|object[14]|person[15]|person[17]	new[13]|new[14]|new[15]|new[17]	ana	3-1[0_17]
2-50	329-332	and	abstract[13]|object[14]|person[15]|person[17]	new[13]|new[14]|new[15]|new[17]	_	_
2-51	333-340	treated	abstract[13]|object[14]|person[15]|person[17]	new[13]|new[14]|new[15]|new[17]	_	_
2-52	341-343	RA	abstract[13]|object[14]|person[15]|organization|person[17]	new[13]|new[14]|new[15]|giv|new[17]	coref	4-12[25_0]
2-53	344-352	patients	abstract[13]|object[14]|person[15]|person[17]	new[13]|new[14]|new[15]|new[17]	_	_
2-54	353-354	.	_	_	_	_

#Text=They found that the RA-associated microbiome deviated significantly from healthy controls in all sites .
3-1	355-359	They	person	giv	coref	5-1[33_0]
3-2	360-365	found	_	_	_	_
3-3	366-370	that	_	_	_	_
3-4	371-374	the	abstract[19]	new[19]	coref	7-1[51_19]
3-5	375-388	RA-associated	abstract[19]	new[19]	_	_
3-6	389-399	microbiome	abstract[19]	new[19]	_	_
3-7	400-408	deviated	_	_	_	_
3-8	409-422	significantly	_	_	_	_
3-9	423-427	from	_	_	_	_
3-10	428-435	healthy	event[20]	new[20]	_	_
3-11	436-444	controls	event[20]	new[20]	_	_
3-12	445-447	in	event[20]	new[20]	_	_
3-13	448-451	all	event[20]|place[21]	new[20]|new[21]	coref	4-30[32_21]
3-14	452-457	sites	event[20]|place[21]	new[20]|new[21]	_	_
3-15	458-459	.	_	_	_	_

#Text=In this study , Haemophilus spp. was depleted in individuals with RA at the fecal and oral levels , whereas Lactobacillus salivarius was over-represented in individuals with RA at both microbiota sites .
4-1	460-462	In	_	_	_	_
4-2	463-467	this	abstract[22]	giv[22]	_	_
4-3	468-473	study	abstract[22]	giv[22]	_	_
4-4	474-475	,	_	_	_	_
4-5	476-487	Haemophilus	abstract	new	_	_
4-6	488-492	spp.	_	_	_	_
4-7	493-496	was	_	_	_	_
4-8	497-505	depleted	_	_	_	_
4-9	506-508	in	_	_	_	_
4-10	509-520	individuals	person[24]	new[24]	coref	4-26[29_24]
4-11	521-525	with	person[24]	new[24]	_	_
4-12	526-528	RA	person[24]|organization[25]	new[24]|giv[25]	coref	4-28[0_25]
4-13	529-531	at	person[24]|organization[25]	new[24]|giv[25]	_	_
4-14	532-535	the	person[24]|organization[25]|substance[26]|abstract[27]	new[24]|giv[25]|giv[26]|giv[27]	_	_
4-15	536-541	fecal	person[24]|organization[25]|substance[26]|abstract[27]	new[24]|giv[25]|giv[26]|giv[27]	_	_
4-16	542-545	and	person[24]|organization[25]|abstract[27]	new[24]|giv[25]|giv[27]	_	_
4-17	546-550	oral	person[24]|organization[25]|abstract[27]|abstract[28]	new[24]|giv[25]|giv[27]|new[28]	_	_
4-18	551-557	levels	person[24]|organization[25]|abstract[27]|abstract[28]	new[24]|giv[25]|giv[27]|new[28]	_	_
4-19	558-559	,	_	_	_	_
4-20	560-567	whereas	_	_	_	_
4-21	568-581	Lactobacillus	_	_	_	_
4-22	582-592	salivarius	_	_	_	_
4-23	593-596	was	_	_	_	_
4-24	597-613	over-represented	_	_	_	_
4-25	614-616	in	_	_	_	_
4-26	617-628	individuals	person[29]	giv[29]	_	_
4-27	629-633	with	person[29]	giv[29]	_	_
4-28	634-636	RA	person[29]|organization	giv[29]|giv	ana	5-10
4-29	637-639	at	person[29]	giv[29]	_	_
4-30	640-644	both	person[29]|place[32]	giv[29]|giv[32]	_	_
4-31	645-655	microbiota	person[29]|abstract|place[32]	giv[29]|giv|giv[32]	coref	6-3[39_0]
4-32	656-661	sites	person[29]|place[32]	giv[29]|giv[32]	_	_
4-33	662-663	.	_	_	_	_

#Text=Older patients often manifest more severe diseases , and this appears connected to age-related gut dysbiosis .
5-1	664-669	Older	person[33]	giv[33]	coref	9-38[84_33]
5-2	670-678	patients	person[33]	giv[33]	_	_
5-3	679-684	often	_	_	_	_
5-4	685-693	manifest	_	_	_	_
5-5	694-698	more	abstract[34]	new[34]	coref	7-13[0_34]
5-6	699-705	severe	abstract[34]	new[34]	_	_
5-7	706-714	diseases	abstract[34]	new[34]	_	_
5-8	715-716	,	_	_	_	_
5-9	717-720	and	_	_	_	_
5-10	721-725	this	organization	giv	coref	8-28
5-11	726-733	appears	_	_	_	_
5-12	734-743	connected	_	_	_	_
5-13	744-746	to	_	_	_	_
5-14	747-758	age-related	abstract[37]	new[37]	_	_
5-15	759-762	gut	abstract|abstract[37]	new|new[37]	coref	10-8
5-16	763-772	dysbiosis	abstract[37]	new[37]	_	_
5-17	773-774	.	_	_	_	_

#Text=Alterations in the microbiota provide plausible candidate mechanisms for driving both inflammation and altering the immune response and host metabolism , which in turn may modulate the development of musculoskeletal problems ( see the Prevotella copri case below ) .
6-1	775-786	Alterations	abstract[38]	new[38]	coref	19-22[172_38]
6-2	787-789	in	abstract[38]	new[38]	_	_
6-3	790-793	the	abstract[38]|abstract[39]	new[38]|giv[39]	coref	8-3[61_39]
6-4	794-804	microbiota	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
6-5	805-812	provide	_	_	_	_
6-6	813-822	plausible	abstract[41]	new[41]	coref	10-18[90_41]
6-7	823-832	candidate	person|abstract[41]	new|new[41]	_	_
6-8	833-843	mechanisms	abstract[41]	new[41]	_	_
6-9	844-847	for	_	_	_	_
6-10	848-855	driving	_	_	_	_
6-11	856-860	both	abstract[42]	new[42]	coref	17-18[0_42]
6-12	861-873	inflammation	abstract[42]	new[42]	_	_
6-13	874-877	and	_	_	_	_
6-14	878-886	altering	_	_	_	_
6-15	887-890	the	abstract[43]	new[43]	_	_
6-16	891-897	immune	abstract[43]	new[43]	_	_
6-17	898-906	response	abstract[43]	new[43]	_	_
6-18	907-910	and	_	_	_	_
6-19	911-915	host	person|abstract[45]	new|new[45]	_	_
6-20	916-926	metabolism	abstract[45]	new[45]	_	_
6-21	927-928	,	_	_	_	_
6-22	929-934	which	_	_	_	_
6-23	935-937	in	_	_	_	_
6-24	938-942	turn	_	_	_	_
6-25	943-946	may	_	_	_	_
6-26	947-955	modulate	_	_	_	_
6-27	956-959	the	event[46]	new[46]	_	_
6-28	960-971	development	event[46]	new[46]	_	_
6-29	972-974	of	event[46]	new[46]	_	_
6-30	975-990	musculoskeletal	event[46]|abstract[47]	new[46]|new[47]	_	_
6-31	991-999	problems	event[46]|abstract[47]	new[46]|new[47]	_	_
6-32	1000-1001	(	_	_	_	_
6-33	1002-1005	see	_	_	_	_
6-34	1006-1009	the	abstract[50]	new[50]	_	_
6-35	1010-1020	Prevotella	object|abstract[50]	new|new[50]	coref	17-44
6-36	1021-1026	copri	person|abstract[50]	new|new[50]	coref	18-2[163_0]
6-37	1027-1031	case	abstract[50]	new[50]	_	_
6-38	1032-1037	below	_	_	_	_
6-39	1038-1039	)	_	_	_	_
6-40	1040-1041	.	_	_	_	_

#Text=The microbiome is thus a highly plausible target for the modulation of diseases of aging owing to its close relationship with innate and adaptive immune systems .
7-1	1042-1045	The	abstract[51]	giv[51]	coref	7-4[52_51]
7-2	1046-1056	microbiome	abstract[51]	giv[51]	_	_
7-3	1057-1059	is	_	_	_	_
7-4	1060-1064	thus	abstract[52]	giv[52]	coref	19-24[173_52]
7-5	1065-1066	a	abstract[52]	giv[52]	_	_
7-6	1067-1073	highly	abstract[52]	giv[52]	_	_
7-7	1074-1083	plausible	abstract[52]	giv[52]	_	_
7-8	1084-1090	target	abstract[52]	giv[52]	_	_
7-9	1091-1094	for	abstract[52]	giv[52]	_	_
7-10	1095-1098	the	abstract[52]|abstract[53]	giv[52]|new[53]	coref	13-5[0_53]
7-11	1099-1109	modulation	abstract[52]|abstract[53]	giv[52]|new[53]	_	_
7-12	1110-1112	of	abstract[52]|abstract[53]	giv[52]|new[53]	_	_
7-13	1113-1121	diseases	abstract[52]|abstract[53]|abstract	giv[52]|new[53]|giv	coref	8-25[68_0]
7-14	1122-1124	of	_	_	_	_
7-15	1125-1130	aging	abstract	new	ana	7-18
7-16	1131-1136	owing	_	_	_	_
7-17	1137-1139	to	_	_	_	_
7-18	1140-1143	its	abstract|abstract[57]	giv|new[57]	_	_
7-19	1144-1149	close	abstract[57]	new[57]	_	_
7-20	1150-1162	relationship	abstract[57]	new[57]	_	_
7-21	1163-1167	with	abstract[57]	new[57]	_	_
7-22	1168-1174	innate	abstract[57]|abstract[59]	new[57]|new[59]	_	_
7-23	1175-1178	and	abstract[57]|abstract[59]	new[57]|new[59]	_	_
7-24	1179-1187	adaptive	abstract[57]|abstract[59]	new[57]|new[59]	_	_
7-25	1188-1194	immune	abstract[57]|abstract|abstract[59]	new[57]|new|new[59]	coref	27-23
7-26	1195-1202	systems	abstract[57]|abstract[59]	new[57]|new[59]	_	_
7-27	1203-1204	.	_	_	_	_

#Text=Components of intestinal microbiota can indeed direct key aspects of host immunity , in particular effector T-cell differentiation , which may impact susceptibility to autoimmune diseases and RA in particular .
8-1	1205-1215	Components	object[60]	new[60]	_	_
8-2	1216-1218	of	object[60]	new[60]	_	_
8-3	1219-1229	intestinal	object[60]|abstract[61]	new[60]|giv[61]	coref	10-7[87_61]
8-4	1230-1240	microbiota	object[60]|abstract[61]	new[60]|giv[61]	_	_
8-5	1241-1244	can	_	_	_	_
8-6	1245-1251	indeed	_	_	_	_
8-7	1252-1258	direct	_	_	_	_
8-8	1259-1262	key	abstract[62]	new[62]	_	_
8-9	1263-1270	aspects	abstract[62]	new[62]	_	_
8-10	1271-1273	of	abstract[62]	new[62]	_	_
8-11	1274-1278	host	abstract[62]|abstract[63]	new[62]|new[63]	_	_
8-12	1279-1287	immunity	abstract[62]|abstract[63]	new[62]|new[63]	_	_
8-13	1288-1289	,	abstract[62]|abstract[63]	new[62]|new[63]	_	_
8-14	1290-1292	in	abstract[62]|abstract[63]	new[62]|new[63]	_	_
8-15	1293-1303	particular	abstract[62]|abstract[63]|abstract[65]	new[62]|new[63]|new[65]	coref	10-25[91_65]
8-16	1304-1312	effector	abstract[62]|abstract[63]|person|abstract[65]	new[62]|new[63]|new|new[65]	_	_
8-17	1313-1319	T-cell	abstract[62]|abstract[63]|abstract[65]	new[62]|new[63]|new[65]	_	_
8-18	1320-1335	differentiation	abstract[62]|abstract[63]|abstract[65]	new[62]|new[63]|new[65]	_	_
8-19	1336-1337	,	_	_	_	_
8-20	1338-1343	which	_	_	_	_
8-21	1344-1347	may	_	_	_	_
8-22	1348-1354	impact	_	_	_	_
8-23	1355-1369	susceptibility	abstract[66]	new[66]	_	_
8-24	1370-1372	to	abstract[66]	new[66]	_	_
8-25	1373-1383	autoimmune	abstract[66]|object|abstract[68]	new[66]|new|giv[68]	coref|coref	11-47[111_68]|11-47[111_68]
8-26	1384-1392	diseases	abstract[66]|abstract[68]	new[66]|giv[68]	_	_
8-27	1393-1396	and	abstract[66]|abstract[68]	new[66]|giv[68]	_	_
8-28	1397-1399	RA	abstract[66]|abstract[68]|organization	new[66]|giv[68]|giv	coref	9-7
8-29	1400-1402	in	_	_	_	_
8-30	1403-1413	particular	_	_	_	_
8-31	1414-1415	.	_	_	_	_

#Text=Different studies investigating the etiology of RA have established the involvement of regulatory T ( T-reg ) cells , which are defective at suppressing IFN-γ and TNF-α production by conventional T cells in the peripheral blood of active RA patients .
9-1	1416-1425	Different	abstract[70]	new[70]	coref	19-1[170_70]
9-2	1426-1433	studies	abstract[70]	new[70]	_	_
9-3	1434-1447	investigating	_	_	_	_
9-4	1448-1451	the	abstract[71]	new[71]	_	_
9-5	1452-1460	etiology	abstract[71]	new[71]	_	_
9-6	1461-1463	of	abstract[71]	new[71]	_	_
9-7	1464-1466	RA	abstract[71]|organization	new[71]|giv	coref	9-39
9-8	1467-1471	have	_	_	_	_
9-9	1472-1483	established	_	_	_	_
9-10	1484-1487	the	abstract[73]	new[73]	_	_
9-11	1488-1499	involvement	abstract[73]	new[73]	_	_
9-12	1500-1502	of	abstract[73]	new[73]	_	_
9-13	1503-1513	regulatory	abstract[73]|person[74]	new[73]|new[74]	coref	9-31[0_74]
9-14	1514-1515	T	abstract[73]|person[74]	new[73]|new[74]	_	_
9-15	1516-1517	(	abstract[73]	new[73]	_	_
9-16	1518-1523	T-reg	abstract[73]|abstract	new[73]|new	coref	10-34
9-17	1524-1525	)	abstract[73]	new[73]	_	_
9-18	1526-1531	cells	abstract[73]|object	new[73]|new	coref	9-30[81_0]
9-19	1532-1533	,	_	_	_	_
9-20	1534-1539	which	_	_	_	_
9-21	1540-1543	are	_	_	_	_
9-22	1544-1553	defective	_	_	_	_
9-23	1554-1556	at	_	_	_	_
9-24	1557-1568	suppressing	_	_	_	_
9-25	1569-1574	IFN-γ	abstract	new	_	_
9-26	1575-1578	and	_	_	_	_
9-27	1579-1584	TNF-α	object|abstract[79]	new|new[79]	ana|ana	10-1[0_79]|10-1[0_79]
9-28	1585-1595	production	abstract[79]	new[79]	_	_
9-29	1596-1598	by	_	_	_	_
9-30	1599-1611	conventional	object[81]	giv[81]	coref	10-33[95_81]
9-31	1612-1613	T	person|object[81]	giv|giv[81]	coref	13-14
9-32	1614-1619	cells	object[81]	giv[81]	_	_
9-33	1620-1622	in	object[81]	giv[81]	_	_
9-34	1623-1626	the	object[81]|substance[82]	giv[81]|new[82]	_	_
9-35	1627-1637	peripheral	object[81]|substance[82]	giv[81]|new[82]	_	_
9-36	1638-1643	blood	object[81]|substance[82]	giv[81]|new[82]	_	_
9-37	1644-1646	of	object[81]|substance[82]	giv[81]|new[82]	_	_
9-38	1647-1653	active	object[81]|substance[82]|person[84]	giv[81]|new[82]|giv[84]	coref	17-40[159_84]
9-39	1654-1656	RA	object[81]|substance[82]|organization|person[84]	giv[81]|new[82]|giv|giv[84]	coref	16-20
9-40	1657-1665	patients	object[81]|substance[82]|person[84]	giv[81]|new[82]|giv[84]	_	_
9-41	1666-1667	.	_	_	_	_

#Text=It has been well established that the gut microbiota – immune interaction and homeostasis , via balancing pro- and anti-inflammatory mechanisms , can regulate the differentiation of various T cell types , especially T-reg cells .
10-1	1668-1670	It	abstract	giv	_	_
10-2	1671-1674	has	_	_	_	_
10-3	1675-1679	been	_	_	_	_
10-4	1680-1684	well	_	_	_	_
10-5	1685-1696	established	_	_	_	_
10-6	1697-1701	that	_	_	_	_
10-7	1702-1705	the	abstract[87]	giv[87]	coref	14-6[0_87]
10-8	1706-1709	gut	abstract|abstract[87]	giv|giv[87]	coref	15-9
10-9	1710-1720	microbiota	abstract[87]	giv[87]	_	_
10-10	1721-1722	–	_	_	_	_
10-11	1723-1729	immune	event[88]	new[88]	_	_
10-12	1730-1741	interaction	event[88]	new[88]	_	_
10-13	1742-1745	and	_	_	_	_
10-14	1746-1757	homeostasis	abstract	new	_	_
10-15	1758-1759	,	_	_	_	_
10-16	1760-1763	via	_	_	_	_
10-17	1764-1773	balancing	_	_	_	_
10-18	1774-1778	pro-	abstract[90]	giv[90]	_	_
10-19	1779-1782	and	abstract[90]	giv[90]	_	_
10-20	1783-1800	anti-inflammatory	abstract[90]	giv[90]	_	_
10-21	1801-1811	mechanisms	abstract[90]	giv[90]	_	_
10-22	1812-1813	,	_	_	_	_
10-23	1814-1817	can	_	_	_	_
10-24	1818-1826	regulate	_	_	_	_
10-25	1827-1830	the	abstract[91]	giv[91]	coref	11-35[107_91]
10-26	1831-1846	differentiation	abstract[91]	giv[91]	_	_
10-27	1847-1849	of	abstract[91]	giv[91]	_	_
10-28	1850-1857	various	abstract[91]|abstract[93]	giv[91]|new[93]	_	_
10-29	1858-1859	T	abstract[91]|abstract[93]	giv[91]|new[93]	_	_
10-30	1860-1864	cell	abstract[91]|object|abstract[93]	giv[91]|new|new[93]	coref	11-36
10-31	1865-1870	types	abstract[91]|abstract[93]	giv[91]|new[93]	_	_
10-32	1871-1872	,	_	_	_	_
10-33	1873-1883	especially	object[95]	giv[95]	coref	13-14[127_95]
10-34	1884-1889	T-reg	object|object[95]	giv|giv[95]	coref	11-35
10-35	1890-1895	cells	object[95]	giv[95]	_	_
10-36	1896-1897	.	_	_	_	_

#Text=A clear example is the potential therapeutic effect of SCFAs ( short chain fatty acids ) , which are microbial fermentation products found in the bowel , that have demonstrated a profound influence on T-reg cell differentiation in a variety of experimental models of autoimmunity or inflammatory T-cell-mediated diseases .
11-1	1898-1899	A	abstract[96]	new[96]	coref	11-5[97_96]
11-2	1900-1905	clear	abstract[96]	new[96]	_	_
11-3	1906-1913	example	abstract[96]	new[96]	_	_
11-4	1914-1916	is	_	_	_	_
11-5	1917-1920	the	abstract[97]	giv[97]	_	_
11-6	1921-1930	potential	abstract[97]	giv[97]	_	_
11-7	1931-1942	therapeutic	abstract[97]	giv[97]	_	_
11-8	1943-1949	effect	abstract[97]	giv[97]	_	_
11-9	1950-1952	of	abstract[97]	giv[97]	_	_
11-10	1953-1958	SCFAs	abstract[97]|abstract	giv[97]|new	_	_
11-11	1959-1960	(	_	_	_	_
11-12	1961-1966	short	substance[100]	new[100]	_	_
11-13	1967-1972	chain	substance[100]	new[100]	_	_
11-14	1973-1978	fatty	abstract|substance[100]	new|new[100]	_	_
11-15	1979-1984	acids	substance[100]	new[100]	_	_
11-16	1985-1986	)	_	_	_	_
11-17	1987-1988	,	_	_	_	_
11-18	1989-1994	which	_	_	_	_
11-19	1995-1998	are	_	_	_	_
11-20	1999-2008	microbial	abstract[102]	new[102]	_	_
11-21	2009-2021	fermentation	abstract|abstract[102]	new|new[102]	_	_
11-22	2022-2030	products	abstract[102]	new[102]	_	_
11-23	2031-2036	found	_	_	_	_
11-24	2037-2039	in	_	_	_	_
11-25	2040-2043	the	object[103]	new[103]	_	_
11-26	2044-2049	bowel	object[103]	new[103]	_	_
11-27	2050-2051	,	_	_	_	_
11-28	2052-2056	that	_	_	_	_
11-29	2057-2061	have	_	_	_	_
11-30	2062-2074	demonstrated	_	_	_	_
11-31	2075-2076	a	abstract[104]	new[104]	_	_
11-32	2077-2085	profound	abstract[104]	new[104]	_	_
11-33	2086-2095	influence	abstract[104]	new[104]	_	_
11-34	2096-2098	on	abstract[104]	new[104]	_	_
11-35	2099-2104	T-reg	abstract[104]|object|abstract[107]	new[104]|giv|giv[107]	coref|coref	13-17|13-17
11-36	2105-2109	cell	abstract[104]|place|abstract[107]	new[104]|giv|giv[107]	_	_
11-37	2110-2125	differentiation	abstract[104]|abstract[107]	new[104]|giv[107]	_	_
11-38	2126-2128	in	abstract[104]|abstract[107]	new[104]|giv[107]	_	_
11-39	2129-2130	a	abstract[104]|abstract[107]|abstract[108]	new[104]|giv[107]|new[108]	_	_
11-40	2131-2138	variety	abstract[104]|abstract[107]|abstract[108]	new[104]|giv[107]|new[108]	_	_
11-41	2139-2141	of	abstract[104]|abstract[107]|abstract[108]	new[104]|giv[107]|new[108]	_	_
11-42	2142-2154	experimental	abstract[104]|abstract[107]|abstract[108]|abstract[109]	new[104]|giv[107]|new[108]|new[109]	_	_
11-43	2155-2161	models	abstract[104]|abstract[107]|abstract[108]|abstract[109]	new[104]|giv[107]|new[108]|new[109]	_	_
11-44	2162-2164	of	abstract[104]|abstract[107]|abstract[108]|abstract[109]	new[104]|giv[107]|new[108]|new[109]	_	_
11-45	2165-2177	autoimmunity	abstract[104]|abstract[107]|abstract[108]|abstract[109]|abstract	new[104]|giv[107]|new[108]|new[109]|new	_	_
11-46	2178-2180	or	abstract[104]|abstract[107]|abstract[108]|abstract[109]	new[104]|giv[107]|new[108]|new[109]	_	_
11-47	2181-2193	inflammatory	abstract[104]|abstract[107]|abstract[108]|abstract[109]|abstract[111]	new[104]|giv[107]|new[108]|new[109]|giv[111]	_	_
11-48	2194-2209	T-cell-mediated	abstract[104]|abstract[107]|abstract[108]|abstract[109]|abstract[111]	new[104]|giv[107]|new[108]|new[109]|giv[111]	_	_
11-49	2210-2218	diseases	abstract[104]|abstract[107]|abstract[108]|abstract[109]|abstract[111]	new[104]|giv[107]|new[108]|new[109]|giv[111]	_	_
11-50	2219-2220	.	_	_	_	_

#Text=An elegant collagen-induced arthritis mouse model published by Hui et al. demonstrated that butyrate ( a functional SCFA ) administration inhibited arthritis by suppressing the expression of inflammatory cytokines .
12-1	2221-2223	An	abstract[114]	new[114]	_	_
12-2	2224-2231	elegant	abstract[114]	new[114]	_	_
12-3	2232-2248	collagen-induced	abstract[114]	new[114]	_	_
12-4	2249-2258	arthritis	abstract|abstract[114]	new|new[114]	coref	12-22
12-5	2259-2264	mouse	animal|abstract[114]	new|new[114]	_	_
12-6	2265-2270	model	abstract[114]	new[114]	_	_
12-7	2271-2280	published	_	_	_	_
12-8	2281-2283	by	_	_	_	_
12-9	2284-2287	Hui	person	new	_	_
12-10	2288-2290	et	_	_	_	_
12-11	2291-2294	al.	_	_	_	_
12-12	2295-2307	demonstrated	_	_	_	_
12-13	2308-2312	that	_	_	_	_
12-14	2313-2321	butyrate	substance[116]	new[116]	_	_
12-15	2322-2323	(	substance[116]|organization[118]	new[116]|new[118]	_	_
12-16	2324-2325	a	substance[116]|organization[118]	new[116]|new[118]	_	_
12-17	2326-2336	functional	substance[116]|substance[117]|organization[118]	new[116]|new[117]|new[118]	_	_
12-18	2337-2341	SCFA	substance[116]|substance[117]|organization[118]	new[116]|new[117]|new[118]	_	_
12-19	2342-2343	)	substance[116]|organization[118]	new[116]|new[118]	_	_
12-20	2344-2358	administration	substance[116]|organization[118]	new[116]|new[118]	_	_
12-21	2359-2368	inhibited	_	_	_	_
12-22	2369-2378	arthritis	abstract	giv	coref	14-13[137_0]
12-23	2379-2381	by	_	_	_	_
12-24	2382-2393	suppressing	_	_	_	_
12-25	2394-2397	the	abstract[120]	new[120]	_	_
12-26	2398-2408	expression	abstract[120]	new[120]	_	_
12-27	2409-2411	of	abstract[120]	new[120]	_	_
12-28	2412-2424	inflammatory	abstract[120]|abstract[121]	new[120]|new[121]	_	_
12-29	2425-2434	cytokines	abstract[120]|abstract[121]	new[120]|new[121]	_	_
12-30	2435-2436	.	_	_	_	_

#Text=The authors suggested that modulation was likely mediated by the differentiation of CD4 T cells towards T-reg cells , which produce anti-inflammatory cytokine IL-10 , and thus influenced the function of Th17 cells .
13-1	2437-2440	The	person[122]	new[122]	_	_
13-2	2441-2448	authors	person[122]	new[122]	_	_
13-3	2449-2458	suggested	_	_	_	_
13-4	2459-2463	that	_	_	_	_
13-5	2464-2474	modulation	abstract	giv	_	_
13-6	2475-2478	was	_	_	_	_
13-7	2479-2485	likely	_	_	_	_
13-8	2486-2494	mediated	_	_	_	_
13-9	2495-2497	by	_	_	_	_
13-10	2498-2501	the	abstract[124]	new[124]	_	_
13-11	2502-2517	differentiation	abstract[124]	new[124]	_	_
13-12	2518-2520	of	abstract[124]	new[124]	_	_
13-13	2521-2524	CD4	abstract[124]|abstract	new[124]|new	_	_
13-14	2525-2526	T	abstract[124]|person|object[127]	new[124]|giv|giv[127]	coref|coref	13-17[129_127]|13-17[129_127]
13-15	2527-2532	cells	abstract[124]|object[127]	new[124]|giv[127]	_	_
13-16	2533-2540	towards	abstract[124]	new[124]	_	_
13-17	2541-2546	T-reg	abstract[124]|object|object[129]	new[124]|giv|giv[129]	coref|coref	13-32[134_129]|13-32[134_129]
13-18	2547-2552	cells	abstract[124]|object[129]	new[124]|giv[129]	_	_
13-19	2553-2554	,	_	_	_	_
13-20	2555-2560	which	_	_	_	_
13-21	2561-2568	produce	_	_	_	_
13-22	2569-2586	anti-inflammatory	time[131]	new[131]	_	_
13-23	2587-2595	cytokine	abstract|time[131]	new|new[131]	_	_
13-24	2596-2601	IL-10	time[131]	new[131]	_	_
13-25	2602-2603	,	_	_	_	_
13-26	2604-2607	and	_	_	_	_
13-27	2608-2612	thus	_	_	_	_
13-28	2613-2623	influenced	_	_	_	_
13-29	2624-2627	the	abstract[132]	new[132]	_	_
13-30	2628-2636	function	abstract[132]	new[132]	_	_
13-31	2637-2639	of	abstract[132]	new[132]	_	_
13-32	2640-2644	Th17	abstract[132]|substance|object[134]	new[132]|new|giv[134]	_	_
13-33	2645-2650	cells	abstract[132]|object[134]	new[132]|giv[134]	_	_
13-34	2651-2652	.	_	_	_	_

#Text=As mentioned , an altered microbiota profile has also been associated with juvenile idiopathic arthritis ( JIA ) .
14-1	2653-2655	As	_	_	_	_
14-2	2656-2665	mentioned	_	_	_	_
14-3	2666-2667	,	_	_	_	_
14-4	2668-2670	an	abstract[136]	new[136]	_	_
14-5	2671-2678	altered	abstract[136]	new[136]	_	_
14-6	2679-2689	microbiota	abstract|abstract[136]	giv|new[136]	coref	15-9[142_0]
14-7	2690-2697	profile	abstract[136]	new[136]	_	_
14-8	2698-2701	has	_	_	_	_
14-9	2702-2706	also	_	_	_	_
14-10	2707-2711	been	_	_	_	_
14-11	2712-2722	associated	_	_	_	_
14-12	2723-2727	with	_	_	_	_
14-13	2728-2736	juvenile	abstract[137]	giv[137]	_	_
14-14	2737-2747	idiopathic	abstract[137]	giv[137]	_	_
14-15	2748-2757	arthritis	abstract[137]	giv[137]	_	_
14-16	2758-2759	(	_	_	_	_
14-17	2760-2763	JIA	person	new	coref	15-17
14-18	2764-2765	)	_	_	_	_
14-19	2766-2767	.	_	_	_	_

#Text=Current evidence indeed suggests that the perturbation of gut microbiota may contribute to the development of JIA .
15-1	2768-2775	Current	abstract[139]	new[139]	_	_
15-2	2776-2784	evidence	abstract[139]	new[139]	_	_
15-3	2785-2791	indeed	_	_	_	_
15-4	2792-2800	suggests	_	_	_	_
15-5	2801-2805	that	_	_	_	_
15-6	2806-2809	the	abstract[140]	new[140]	_	_
15-7	2810-2822	perturbation	abstract[140]	new[140]	_	_
15-8	2823-2825	of	abstract[140]	new[140]	_	_
15-9	2826-2829	gut	abstract[140]|abstract|abstract[142]	new[140]|giv|giv[142]	coref|coref|coref|coref	20-4[180_142]|25-25|20-4[180_142]|25-25
15-10	2830-2840	microbiota	abstract[140]|abstract[142]	new[140]|giv[142]	_	_
15-11	2841-2844	may	_	_	_	_
15-12	2845-2855	contribute	_	_	_	_
15-13	2856-2858	to	_	_	_	_
15-14	2859-2862	the	event[143]	new[143]	ana	16-1[0_143]
15-15	2863-2874	development	event[143]	new[143]	_	_
15-16	2875-2877	of	event[143]	new[143]	_	_
15-17	2878-2881	JIA	event[143]|person	new[143]|giv	_	_
15-18	2882-2883	.	_	_	_	_

#Text=It remains difficult , however , to establish a definitive microbial marker or specific enterotypes that are associated with RA .
16-1	2884-2886	It	event	giv	_	_
16-2	2887-2894	remains	_	_	_	_
16-3	2895-2904	difficult	_	_	_	_
16-4	2905-2906	,	_	_	_	_
16-5	2907-2914	however	_	_	_	_
16-6	2915-2916	,	_	_	_	_
16-7	2917-2919	to	_	_	_	_
16-8	2920-2929	establish	_	_	_	_
16-9	2930-2931	a	abstract[146]	new[146]	ana	17-1[0_146]
16-10	2932-2942	definitive	abstract[146]	new[146]	_	_
16-11	2943-2952	microbial	abstract[146]	new[146]	_	_
16-12	2953-2959	marker	abstract[146]	new[146]	_	_
16-13	2960-2962	or	_	_	_	_
16-14	2963-2971	specific	object[147]	new[147]	_	_
16-15	2972-2983	enterotypes	object[147]	new[147]	_	_
16-16	2984-2988	that	_	_	_	_
16-17	2989-2992	are	_	_	_	_
16-18	2993-3003	associated	_	_	_	_
16-19	3004-3008	with	_	_	_	_
16-20	3009-3011	RA	organization	giv	coref	17-40
16-21	3012-3013	.	_	_	_	_

#Text=It has been hypothesized that the alteration of single bacterial genus could have direct impact on driving inflammation , as suggested for Bacteroides , Akkermansia or the anti-inflammatory Faecalobacterium prausnitzii , which has been noted to be depleted in RA patients , while Prevotella and Ruminococcus were more prevalent .
17-1	3014-3016	It	abstract	giv	_	_
17-2	3017-3020	has	_	_	_	_
17-3	3021-3025	been	_	_	_	_
17-4	3026-3038	hypothesized	_	_	_	_
17-5	3039-3043	that	_	_	_	_
17-6	3044-3047	the	event[150]	new[150]	_	_
17-7	3048-3058	alteration	event[150]	new[150]	_	_
17-8	3059-3061	of	event[150]	new[150]	_	_
17-9	3062-3068	single	event[150]|abstract[152]	new[150]|new[152]	_	_
17-10	3069-3078	bacterial	event[150]|substance|abstract[152]	new[150]|new|new[152]	coref	26-31
17-11	3079-3084	genus	event[150]|abstract[152]	new[150]|new[152]	_	_
17-12	3085-3090	could	_	_	_	_
17-13	3091-3095	have	_	_	_	_
17-14	3096-3102	direct	abstract[153]	new[153]	_	_
17-15	3103-3109	impact	abstract[153]	new[153]	_	_
17-16	3110-3112	on	_	_	_	_
17-17	3113-3120	driving	_	_	_	_
17-18	3121-3133	inflammation	abstract	giv	coref	30-6[253_0]
17-19	3134-3135	,	_	_	_	_
17-20	3136-3138	as	_	_	_	_
17-21	3139-3148	suggested	_	_	_	_
17-22	3149-3152	for	_	_	_	_
17-23	3153-3164	Bacteroides	abstract	new	coref	18-6
17-24	3165-3166	,	_	_	_	_
17-25	3167-3178	Akkermansia	person	new	_	_
17-26	3179-3181	or	_	_	_	_
17-27	3182-3185	the	_	_	_	_
17-28	3186-3203	anti-inflammatory	_	_	_	_
17-29	3204-3220	Faecalobacterium	animal	new	_	_
17-30	3221-3232	prausnitzii	_	_	_	_
17-31	3233-3234	,	_	_	_	_
17-32	3235-3240	which	_	_	_	_
17-33	3241-3244	has	_	_	_	_
17-34	3245-3249	been	_	_	_	_
17-35	3250-3255	noted	_	_	_	_
17-36	3256-3258	to	_	_	_	_
17-37	3259-3261	be	_	_	_	_
17-38	3262-3270	depleted	_	_	_	_
17-39	3271-3273	in	_	_	_	_
17-40	3274-3276	RA	organization|person[159]	giv|giv[159]	coref|coref|coref|coref	18-19[168_0]|30-73[276_159]|18-19[168_0]|30-73[276_159]
17-41	3277-3285	patients	person[159]	giv[159]	_	_
17-42	3286-3287	,	_	_	_	_
17-43	3288-3293	while	_	_	_	_
17-44	3294-3304	Prevotella	abstract	giv	coref	18-2
17-45	3305-3308	and	_	_	_	_
17-46	3309-3321	Ruminococcus	animal	new	_	_
17-47	3322-3326	were	_	_	_	_
17-48	3327-3331	more	_	_	_	_
17-49	3332-3341	prevalent	_	_	_	_
17-50	3342-3343	.	_	_	_	_

#Text=Increasing Prevotella copri and decreasing Bacteroides concentrations in the stool have both been associated with new onset , untreated RA in humans .
18-1	3344-3354	Increasing	_	_	_	_
18-2	3355-3365	Prevotella	substance|person[163]	giv|giv[163]	_	_
18-3	3366-3371	copri	person[163]	giv[163]	_	_
18-4	3372-3375	and	_	_	_	_
18-5	3376-3386	decreasing	animal[165]	new[165]	coref	30-50[268_165]
18-6	3387-3398	Bacteroides	substance|animal[165]	giv|new[165]	coref	25-32
18-7	3399-3413	concentrations	animal[165]	new[165]	_	_
18-8	3414-3416	in	animal[165]	new[165]	_	_
18-9	3417-3420	the	animal[165]|object[166]	new[165]|new[166]	_	_
18-10	3421-3426	stool	animal[165]|object[166]	new[165]|new[166]	_	_
18-11	3427-3431	have	_	_	_	_
18-12	3432-3436	both	_	_	_	_
18-13	3437-3441	been	_	_	_	_
18-14	3442-3452	associated	_	_	_	_
18-15	3453-3457	with	_	_	_	_
18-16	3458-3461	new	abstract[167]	new[167]	coref	30-66[273_167]
18-17	3462-3467	onset	abstract[167]	new[167]	_	_
18-18	3468-3469	,	_	_	_	_
18-19	3470-3479	untreated	organization[168]	giv[168]	_	_
18-20	3480-3482	RA	organization[168]	giv[168]	_	_
18-21	3483-3485	in	_	_	_	_
18-22	3486-3492	humans	person	new	_	_
18-23	3493-3494	.	_	_	_	_

#Text=The above studies , although not always homogenous , have directly or indirectly demonstrated that genetic risk may be modulated by alterations in the microbiome and that the presence of particular microbial markers can be predictive of disease .
19-1	3495-3498	The	abstract[170]	giv[170]	_	_
19-2	3499-3504	above	abstract[170]	giv[170]	_	_
19-3	3505-3512	studies	abstract[170]	giv[170]	_	_
19-4	3513-3514	,	_	_	_	_
19-5	3515-3523	although	_	_	_	_
19-6	3524-3527	not	_	_	_	_
19-7	3528-3534	always	_	_	_	_
19-8	3535-3545	homogenous	_	_	_	_
19-9	3546-3547	,	_	_	_	_
19-10	3548-3552	have	_	_	_	_
19-11	3553-3561	directly	_	_	_	_
19-12	3562-3564	or	_	_	_	_
19-13	3565-3575	indirectly	_	_	_	_
19-14	3576-3588	demonstrated	_	_	_	_
19-15	3589-3593	that	_	_	_	_
19-16	3594-3601	genetic	abstract[171]	new[171]	coref	23-14[0_171]
19-17	3602-3606	risk	abstract[171]	new[171]	_	_
19-18	3607-3610	may	_	_	_	_
19-19	3611-3613	be	_	_	_	_
19-20	3614-3623	modulated	_	_	_	_
19-21	3624-3626	by	_	_	_	_
19-22	3627-3638	alterations	abstract[172]	giv[172]	_	_
19-23	3639-3641	in	abstract[172]	giv[172]	_	_
19-24	3642-3645	the	abstract[172]|abstract[173]	giv[172]|giv[173]	coref	28-18[243_173]
19-25	3646-3656	microbiome	abstract[172]|abstract[173]	giv[172]|giv[173]	_	_
19-26	3657-3660	and	_	_	_	_
19-27	3661-3665	that	_	_	_	_
19-28	3666-3669	the	abstract[174]	new[174]	coref	19-36[177_174]
19-29	3670-3678	presence	abstract[174]	new[174]	_	_
19-30	3679-3681	of	abstract[174]	new[174]	_	_
19-31	3682-3692	particular	abstract[174]|abstract[176]	new[174]|new[176]	_	_
19-32	3693-3702	microbial	abstract[174]|place|abstract[176]	new[174]|new|new[176]	_	_
19-33	3703-3710	markers	abstract[174]|abstract[176]	new[174]|new[176]	_	_
19-34	3711-3714	can	_	_	_	_
19-35	3715-3717	be	_	_	_	_
19-36	3718-3728	predictive	abstract[177]	giv[177]	_	_
19-37	3729-3731	of	abstract[177]	giv[177]	_	_
19-38	3732-3739	disease	abstract[177]|abstract	giv[177]|new	coref	21-20
19-39	3740-3741	.	_	_	_	_

#Text=As mentioned , intestinal microbiota are also known to change with age .
20-1	3742-3744	As	_	_	_	_
20-2	3745-3754	mentioned	_	_	_	_
20-3	3755-3756	,	_	_	_	_
20-4	3757-3767	intestinal	person|abstract[180]	new|giv[180]	coref|coref	24-11[205_180]|24-11[205_180]
20-5	3768-3778	microbiota	abstract[180]	giv[180]	_	_
20-6	3779-3782	are	_	_	_	_
20-7	3783-3787	also	_	_	_	_
20-8	3788-3793	known	_	_	_	_
20-9	3794-3796	to	_	_	_	_
20-10	3797-3803	change	abstract	new	coref|none	21-13[184_0]|20-10[0_184]
20-11	3804-3808	with	_	_	_	_
20-12	3809-3812	age	abstract	new	coref	21-24
20-13	3813-3814	.	_	_	_	_

#Text=Many of the clinical issues , including OA , are related to the inflammatory change — either specific to disease or associated with age .
21-1	3815-3819	Many	_	_	_	_
21-2	3820-3822	of	_	_	_	_
21-3	3823-3826	the	abstract[182]	new[182]	_	_
21-4	3827-3835	clinical	abstract[182]	new[182]	_	_
21-5	3836-3842	issues	abstract[182]	new[182]	_	_
21-6	3843-3844	,	abstract[182]	new[182]	_	_
21-7	3845-3854	including	abstract[182]	new[182]	_	_
21-8	3855-3857	OA	abstract[182]|substance	new[182]|giv	coref	22-1
21-9	3858-3859	,	_	_	_	_
21-10	3860-3863	are	_	_	_	_
21-11	3864-3871	related	_	_	_	_
21-12	3872-3874	to	_	_	_	_
21-13	3875-3878	the	abstract[184]	new[184]	_	_
21-14	3879-3891	inflammatory	abstract[184]	new[184]	_	_
21-15	3892-3898	change	abstract[184]	new[184]	_	_
21-16	3899-3900	—	_	_	_	_
21-17	3901-3907	either	_	_	_	_
21-18	3908-3916	specific	_	_	_	_
21-19	3917-3919	to	_	_	_	_
21-20	3920-3927	disease	abstract	giv	coref	23-22[197_0]
21-21	3928-3930	or	_	_	_	_
21-22	3931-3941	associated	_	_	_	_
21-23	3942-3946	with	_	_	_	_
21-24	3947-3950	age	abstract	giv	coref	22-18[191_0]
21-25	3951-3952	.	_	_	_	_

#Text=OA is indeed considered a degeneration of joint cartilage and the underlying bone which commonly occurs from middle age onward .
22-1	3953-3955	OA	abstract	giv	coref	23-5
22-2	3956-3958	is	_	_	_	_
22-3	3959-3965	indeed	_	_	_	_
22-4	3966-3976	considered	_	_	_	_
22-5	3977-3978	a	event[188]	new[188]	_	_
22-6	3979-3991	degeneration	event[188]	new[188]	_	_
22-7	3992-3994	of	event[188]	new[188]	_	_
22-8	3995-4000	joint	event[188]|object[189]	new[188]|new[189]	_	_
22-9	4001-4010	cartilage	event[188]|object[189]	new[188]|new[189]	_	_
22-10	4011-4014	and	event[188]	new[188]	_	_
22-11	4015-4018	the	event[188]|object[190]	new[188]|new[190]	_	_
22-12	4019-4029	underlying	event[188]|object[190]	new[188]|new[190]	_	_
22-13	4030-4034	bone	event[188]|object[190]	new[188]|new[190]	_	_
22-14	4035-4040	which	_	_	_	_
22-15	4041-4049	commonly	_	_	_	_
22-16	4050-4056	occurs	_	_	_	_
22-17	4057-4061	from	_	_	_	_
22-18	4062-4068	middle	abstract[191]	giv[191]	coref	23-26[0_191]
22-19	4069-4072	age	abstract[191]	giv[191]	_	_
22-20	4073-4079	onward	_	_	_	_
22-21	4080-4081	.	_	_	_	_

#Text=The precise etiology of OA remains unknown thus far , even if various risk factors have been associated with presence of the disease , including age , sex , obesity , and diet , and local joint injury .
23-1	4082-4085	The	abstract[192]	new[192]	_	_
23-2	4086-4093	precise	abstract[192]	new[192]	_	_
23-3	4094-4102	etiology	abstract[192]	new[192]	_	_
23-4	4103-4105	of	abstract[192]	new[192]	_	_
23-5	4106-4108	OA	abstract[192]|abstract	new[192]|giv	coref	28-5
23-6	4109-4116	remains	_	_	_	_
23-7	4117-4124	unknown	_	_	_	_
23-8	4125-4129	thus	_	_	_	_
23-9	4130-4133	far	_	_	_	_
23-10	4134-4135	,	_	_	_	_
23-11	4136-4140	even	_	_	_	_
23-12	4141-4143	if	_	_	_	_
23-13	4144-4151	various	abstract[195]	new[195]	coref	24-1[203_195]
23-14	4152-4156	risk	abstract|abstract[195]	giv|new[195]	_	_
23-15	4157-4164	factors	abstract[195]	new[195]	_	_
23-16	4165-4169	have	_	_	_	_
23-17	4170-4174	been	_	_	_	_
23-18	4175-4185	associated	_	_	_	_
23-19	4186-4190	with	_	_	_	_
23-20	4191-4199	presence	abstract[196]	new[196]	_	_
23-21	4200-4202	of	abstract[196]	new[196]	_	_
23-22	4203-4206	the	abstract[196]|abstract[197]	new[196]|giv[197]	_	_
23-23	4207-4214	disease	abstract[196]|abstract[197]	new[196]|giv[197]	_	_
23-24	4215-4216	,	abstract[196]	new[196]	_	_
23-25	4217-4226	including	abstract[196]	new[196]	_	_
23-26	4227-4230	age	abstract[196]|abstract	new[196]|giv	_	_
23-27	4231-4232	,	abstract[196]	new[196]	_	_
23-28	4233-4236	sex	abstract[196]|abstract	new[196]|new	_	_
23-29	4237-4238	,	abstract[196]	new[196]	_	_
23-30	4239-4246	obesity	abstract[196]|abstract	new[196]|new	coref	26-4
23-31	4247-4248	,	abstract[196]	new[196]	_	_
23-32	4249-4252	and	abstract[196]	new[196]	_	_
23-33	4253-4257	diet	abstract[196]|event	new[196]|new	coref	27-3
23-34	4258-4259	,	abstract[196]	new[196]	_	_
23-35	4260-4263	and	abstract[196]	new[196]	_	_
23-36	4264-4269	local	abstract[196]|event[202]	new[196]|new[202]	_	_
23-37	4270-4275	joint	abstract[196]|event[202]	new[196]|new[202]	_	_
23-38	4276-4282	injury	abstract[196]|event[202]	new[196]|new[202]	_	_
23-39	4283-4284	.	_	_	_	_

#Text=Most of these factors are associated with drastic changes in the intestinal microbiota .
24-1	4285-4289	Most	abstract[203]	giv[203]	coref	28-25[245_203]
24-2	4290-4292	of	abstract[203]	giv[203]	_	_
24-3	4293-4298	these	abstract[203]	giv[203]	_	_
24-4	4299-4306	factors	abstract[203]	giv[203]	_	_
24-5	4307-4310	are	_	_	_	_
24-6	4311-4321	associated	_	_	_	_
24-7	4322-4326	with	_	_	_	_
24-8	4327-4334	drastic	abstract[204]	new[204]	coref	26-8[221_204]
24-9	4335-4342	changes	abstract[204]	new[204]	_	_
24-10	4343-4345	in	abstract[204]	new[204]	_	_
24-11	4346-4349	the	abstract[204]|abstract[205]	new[204]|giv[205]	coref	25-7[207_205]
24-12	4350-4360	intestinal	abstract[204]|abstract[205]	new[204]|giv[205]	_	_
24-13	4361-4371	microbiota	abstract[204]|abstract[205]	new[204]|giv[205]	_	_
24-14	4372-4373	.	_	_	_	_

#Text=Age , in fact , shifts the intestinal microbiota with significant differences between younger adults and older people , showing a lower diversity of gut microbiota , a greater proportion of Bacteroides spp. , and a distinct abundance pattern of Clostridium groups .
25-1	4374-4377	Age	abstract	new	_	_
25-2	4378-4379	,	_	_	_	_
25-3	4380-4382	in	_	_	_	_
25-4	4383-4387	fact	_	_	_	_
25-5	4388-4389	,	_	_	_	_
25-6	4390-4396	shifts	_	_	_	_
25-7	4397-4400	the	abstract[207]	giv[207]	coref	25-25[213_207]
25-8	4401-4411	intestinal	abstract[207]	giv[207]	_	_
25-9	4412-4422	microbiota	abstract[207]	giv[207]	_	_
25-10	4423-4427	with	abstract[207]	giv[207]	_	_
25-11	4428-4439	significant	abstract[207]|abstract[208]	giv[207]|new[208]	_	_
25-12	4440-4451	differences	abstract[207]|abstract[208]	giv[207]|new[208]	_	_
25-13	4452-4459	between	abstract[207]|abstract[208]	giv[207]|new[208]	_	_
25-14	4460-4467	younger	abstract[207]|abstract[208]|person[209]	giv[207]|new[208]|new[209]	_	_
25-15	4468-4474	adults	abstract[207]|abstract[208]|person[209]	giv[207]|new[208]|new[209]	_	_
25-16	4475-4478	and	abstract[207]|abstract[208]	giv[207]|new[208]	_	_
25-17	4479-4484	older	abstract[207]|abstract[208]|person[210]	giv[207]|new[208]|new[210]	_	_
25-18	4485-4491	people	abstract[207]|abstract[208]|person[210]	giv[207]|new[208]|new[210]	_	_
25-19	4492-4493	,	_	_	_	_
25-20	4494-4501	showing	_	_	_	_
25-21	4502-4503	a	abstract[211]	new[211]	coref	26-23[225_211]
25-22	4504-4509	lower	abstract[211]	new[211]	_	_
25-23	4510-4519	diversity	abstract[211]	new[211]	_	_
25-24	4520-4522	of	abstract[211]	new[211]	_	_
25-25	4523-4526	gut	abstract[211]|abstract|abstract[213]	new[211]|giv|giv[213]	coref|coref|coref|coref	26-11[222_213]|27-6|26-11[222_213]|27-6
25-26	4527-4537	microbiota	abstract[211]|abstract[213]	new[211]|giv[213]	_	_
25-27	4538-4539	,	_	_	_	_
25-28	4540-4541	a	quantity[214]	new[214]	_	_
25-29	4542-4549	greater	quantity[214]	new[214]	_	_
25-30	4550-4560	proportion	quantity[214]	new[214]	_	_
25-31	4561-4563	of	quantity[214]	new[214]	_	_
25-32	4564-4575	Bacteroides	quantity[214]|place	new[214]|giv	_	_
25-33	4576-4580	spp.	quantity[214]	new[214]	_	_
25-34	4581-4582	,	_	_	_	_
25-35	4583-4586	and	_	_	_	_
25-36	4587-4588	a	abstract[217]	new[217]	_	_
25-37	4589-4597	distinct	abstract[217]	new[217]	_	_
25-38	4598-4607	abundance	abstract|abstract[217]	new|new[217]	_	_
25-39	4608-4615	pattern	abstract[217]	new[217]	_	_
25-40	4616-4618	of	abstract[217]	new[217]	_	_
25-41	4619-4630	Clostridium	abstract[217]|organization|person[219]	new[217]|new|new[219]	_	_
25-42	4631-4637	groups	abstract[217]|person[219]	new[217]|new[219]	_	_
25-43	4638-4639	.	_	_	_	_

#Text=In addition , obesity is associated with phylum-level changes in the microbiota ( i. e. , ratio of Firmicutes/Bacteroidetes ) , reduced bacterial diversity , and an altered representation of bacterial genes and metabolic pathways .
26-1	4640-4642	In	_	_	_	_
26-2	4643-4651	addition	_	_	_	_
26-3	4652-4653	,	_	_	_	_
26-4	4654-4661	obesity	abstract	giv	_	_
26-5	4662-4664	is	_	_	_	_
26-6	4665-4675	associated	_	_	_	_
26-7	4676-4680	with	_	_	_	_
26-8	4681-4693	phylum-level	abstract[221]	giv[221]	_	_
26-9	4694-4701	changes	abstract[221]	giv[221]	_	_
26-10	4702-4704	in	abstract[221]	giv[221]	_	_
26-11	4705-4708	the	abstract[221]|abstract[222]	giv[221]|giv[222]	appos	26-17[223_222]
26-12	4709-4719	microbiota	abstract[221]|abstract[222]	giv[221]|giv[222]	_	_
26-13	4720-4721	(	abstract[221]	giv[221]	_	_
26-14	4722-4724	i.	abstract[221]	giv[221]	_	_
26-15	4725-4727	e.	abstract[221]	giv[221]	_	_
26-16	4728-4729	,	abstract[221]	giv[221]	_	_
26-17	4730-4735	ratio	abstract[221]|abstract[223]	giv[221]|giv[223]	coref	27-6[232_223]
26-18	4736-4738	of	abstract[221]|abstract[223]	giv[221]|giv[223]	_	_
26-19	4739-4763	Firmicutes/Bacteroidetes	abstract[221]|abstract[223]|substance	giv[221]|giv[223]|new	_	_
26-20	4764-4765	)	abstract[221]	giv[221]	_	_
26-21	4766-4767	,	abstract[221]	giv[221]	_	_
26-22	4768-4775	reduced	abstract[221]	giv[221]	_	_
26-23	4776-4785	bacterial	abstract[221]|abstract[225]	giv[221]|giv[225]	_	_
26-24	4786-4795	diversity	abstract[221]|abstract[225]	giv[221]|giv[225]	_	_
26-25	4796-4797	,	abstract[221]	giv[221]	_	_
26-26	4798-4801	and	abstract[221]	giv[221]	_	_
26-27	4802-4804	an	abstract[221]|abstract[226]	giv[221]|new[226]	_	_
26-28	4805-4812	altered	abstract[221]|abstract[226]	giv[221]|new[226]	_	_
26-29	4813-4827	representation	abstract[221]|abstract[226]	giv[221]|new[226]	_	_
26-30	4828-4830	of	abstract[221]|abstract[226]	giv[221]|new[226]	_	_
26-31	4831-4840	bacterial	abstract[221]|abstract[226]|substance|abstract[228]	giv[221]|new[226]|giv|new[228]	_	_
26-32	4841-4846	genes	abstract[221]|abstract[226]|abstract[228]	giv[221]|new[226]|new[228]	_	_
26-33	4847-4850	and	abstract[221]|abstract[226]	giv[221]|new[226]	_	_
26-34	4851-4860	metabolic	abstract[221]|abstract[226]|abstract[229]	giv[221]|new[226]|new[229]	_	_
26-35	4861-4869	pathways	abstract[221]|abstract[226]|abstract[229]	giv[221]|new[226]|new[229]	_	_
26-36	4870-4871	.	_	_	_	_

#Text=Finally , diet can shape gut microbiota and consequently change the composition and metabolism of intestinal microbiota as well as impact host immune responses .
27-1	4872-4879	Finally	_	_	_	_
27-2	4880-4881	,	_	_	_	_
27-3	4882-4886	diet	event	giv	coref	30-13[254_0]
27-4	4887-4890	can	_	_	_	_
27-5	4891-4896	shape	_	_	_	_
27-6	4897-4900	gut	abstract|abstract[232]	giv|giv[232]	coref|coref|coref|coref	27-16[235_232]|29-14|27-16[235_232]|29-14
27-7	4901-4911	microbiota	abstract[232]	giv[232]	_	_
27-8	4912-4915	and	_	_	_	_
27-9	4916-4928	consequently	_	_	_	_
27-10	4929-4935	change	_	_	_	_
27-11	4936-4939	the	abstract[233]	new[233]	_	_
27-12	4940-4951	composition	abstract[233]	new[233]	_	_
27-13	4952-4955	and	_	_	_	_
27-14	4956-4966	metabolism	abstract[234]	new[234]	_	_
27-15	4967-4969	of	abstract[234]	new[234]	_	_
27-16	4970-4980	intestinal	abstract[234]|abstract[235]	new[234]|giv[235]	coref	29-14[251_235]
27-17	4981-4991	microbiota	abstract[234]|abstract[235]	new[234]|giv[235]	_	_
27-18	4992-4994	as	_	_	_	_
27-19	4995-4999	well	_	_	_	_
27-20	5000-5002	as	_	_	_	_
27-21	5003-5009	impact	abstract[238]	new[238]	_	_
27-22	5010-5014	host	person|abstract[238]	new|new[238]	_	_
27-23	5015-5021	immune	abstract|abstract[238]	giv|new[238]	_	_
27-24	5022-5031	responses	abstract[238]	new[238]	_	_
27-25	5032-5033	.	_	_	_	_

#Text=For these reasons , OA is now considered an induced inflammatory condition in which the role of the microbiome has emerging as one of the most important factors .
28-1	5034-5037	For	_	_	_	_
28-2	5038-5043	these	abstract[239]	new[239]	_	_
28-3	5044-5051	reasons	abstract[239]	new[239]	_	_
28-4	5052-5053	,	_	_	_	_
28-5	5054-5056	OA	abstract	giv	coref	30-71[275_0]
28-6	5057-5059	is	_	_	_	_
28-7	5060-5063	now	_	_	_	_
28-8	5064-5074	considered	_	_	_	_
28-9	5075-5077	an	abstract[241]	new[241]	_	_
28-10	5078-5085	induced	abstract[241]	new[241]	_	_
28-11	5086-5098	inflammatory	abstract[241]	new[241]	_	_
28-12	5099-5108	condition	abstract[241]	new[241]	_	_
28-13	5109-5111	in	_	_	_	_
28-14	5112-5117	which	_	_	_	_
28-15	5118-5121	the	abstract[242]	new[242]	_	_
28-16	5122-5126	role	abstract[242]	new[242]	_	_
28-17	5127-5129	of	abstract[242]	new[242]	_	_
28-18	5130-5133	the	abstract[242]|object[243]	new[242]|giv[243]	_	_
28-19	5134-5144	microbiome	abstract[242]|object[243]	new[242]|giv[243]	_	_
28-20	5145-5148	has	_	_	_	_
28-21	5149-5157	emerging	_	_	_	_
28-22	5158-5160	as	_	_	_	_
28-23	5161-5164	one	abstract[244]	new[244]	_	_
28-24	5165-5167	of	abstract[244]	new[244]	_	_
28-25	5168-5171	the	abstract[244]|abstract[245]	new[244]|giv[245]	_	_
28-26	5172-5176	most	abstract[244]|abstract[245]	new[244]|giv[245]	_	_
28-27	5177-5186	important	abstract[244]|abstract[245]	new[244]|giv[245]	_	_
28-28	5187-5194	factors	abstract[244]|abstract[245]	new[244]|giv[245]	_	_
28-29	5195-5196	.	_	_	_	_

#Text=Several publications have reported a clear demonstration of the link between osteoarthritis and gut microbiota .
29-1	5197-5204	Several	organization[246]	new[246]	_	_
29-2	5205-5217	publications	organization[246]	new[246]	_	_
29-3	5218-5222	have	_	_	_	_
29-4	5223-5231	reported	_	_	_	_
29-5	5232-5233	a	event[247]	new[247]	_	_
29-6	5234-5239	clear	event[247]	new[247]	_	_
29-7	5240-5253	demonstration	event[247]	new[247]	_	_
29-8	5254-5256	of	event[247]	new[247]	_	_
29-9	5257-5260	the	event[247]|abstract[248]	new[247]|new[248]	_	_
29-10	5261-5265	link	event[247]|abstract[248]	new[247]|new[248]	_	_
29-11	5266-5273	between	event[247]|abstract[248]	new[247]|new[248]	_	_
29-12	5274-5288	osteoarthritis	event[247]|abstract[248]|abstract	new[247]|new[248]|new	coref	30-18
29-13	5289-5292	and	event[247]|abstract[248]	new[247]|new[248]	_	_
29-14	5293-5296	gut	event[247]|abstract[248]|abstract|abstract[251]	new[247]|new[248]|giv|giv[251]	_	_
29-15	5297-5307	microbiota	event[247]|abstract[248]|abstract[251]	new[247]|new[248]|giv[251]	_	_
29-16	5308-5309	.	_	_	_	_

#Text=For instance , animals with a low-grade chronic systemic inflammation due to a high-fat diet have developed osteoarthritis , and others with an increased body weight due to diet have shown an increased progression of osteoarthritis . Metcalfe et al. proposed that metabolic endotoxemia ( raised LPS blood and synovial concentrations ) caused by impaired gastric mucosa and low-grade chronic inflammation , may contribute to the onset and progression of OA in obese patients .
30-1	5310-5313	For	_	_	_	_
30-2	5314-5322	instance	_	_	_	_
30-3	5323-5324	,	_	_	_	_
30-4	5325-5332	animals	animal[252]	new[252]	_	_
30-5	5333-5337	with	animal[252]	new[252]	_	_
30-6	5338-5339	a	animal[252]|abstract[253]	new[252]|giv[253]	coref	30-59[272_253]
30-7	5340-5349	low-grade	animal[252]|abstract[253]	new[252]|giv[253]	_	_
30-8	5350-5357	chronic	animal[252]|abstract[253]	new[252]|giv[253]	_	_
30-9	5358-5366	systemic	animal[252]|abstract[253]	new[252]|giv[253]	_	_
30-10	5367-5379	inflammation	animal[252]|abstract[253]	new[252]|giv[253]	_	_
30-11	5380-5383	due	_	_	_	_
30-12	5384-5386	to	_	_	_	_
30-13	5387-5388	a	event[254]	giv[254]	coref	30-29[0_254]
30-14	5389-5397	high-fat	event[254]	giv[254]	_	_
30-15	5398-5402	diet	event[254]	giv[254]	_	_
30-16	5403-5407	have	_	_	_	_
30-17	5408-5417	developed	_	_	_	_
30-18	5418-5432	osteoarthritis	abstract	giv	coref	30-36
30-19	5433-5434	,	_	_	_	_
30-20	5435-5438	and	_	_	_	_
30-21	5439-5445	others	person[256]	new[256]	_	_
30-22	5446-5450	with	person[256]	new[256]	_	_
30-23	5451-5453	an	person[256]|abstract[258]	new[256]|new[258]	_	_
30-24	5454-5463	increased	person[256]|abstract[258]	new[256]|new[258]	_	_
30-25	5464-5468	body	person[256]|object|abstract[258]	new[256]|new|new[258]	_	_
30-26	5469-5475	weight	person[256]|abstract[258]	new[256]|new[258]	_	_
30-27	5476-5479	due	person[256]|abstract[258]	new[256]|new[258]	_	_
30-28	5480-5482	to	_	_	_	_
30-29	5483-5487	diet	event	giv	_	_
30-30	5488-5492	have	_	_	_	_
30-31	5493-5498	shown	_	_	_	_
30-32	5499-5501	an	abstract[260]	new[260]	_	_
30-33	5502-5511	increased	abstract[260]	new[260]	_	_
30-34	5512-5523	progression	abstract[260]	new[260]	_	_
30-35	5524-5526	of	abstract[260]	new[260]	_	_
30-36	5527-5541	osteoarthritis	abstract[260]|abstract	new[260]|giv	_	_
30-37	5542-5543	.	_	_	_	_
30-38	5544-5552	Metcalfe	person	new	_	_
30-39	5553-5555	et	_	_	_	_
30-40	5556-5559	al.	_	_	_	_
30-41	5560-5568	proposed	_	_	_	_
30-42	5569-5573	that	_	_	_	_
30-43	5574-5583	metabolic	person|abstract[264]	new|new[264]	_	_
30-44	5584-5595	endotoxemia	abstract[264]	new[264]	_	_
30-45	5596-5597	(	_	_	_	_
30-46	5598-5604	raised	_	_	_	_
30-47	5605-5608	LPS	animal|substance[266]	new|new[266]	_	_
30-48	5609-5614	blood	substance[266]	new[266]	_	_
30-49	5615-5618	and	_	_	_	_
30-50	5619-5627	synovial	substance|animal[268]	new|giv[268]	_	_
30-51	5628-5642	concentrations	animal[268]	giv[268]	_	_
30-52	5643-5644	)	_	_	_	_
30-53	5645-5651	caused	_	_	_	_
30-54	5652-5654	by	_	_	_	_
30-55	5655-5663	impaired	object[270]	new[270]	_	_
30-56	5664-5671	gastric	abstract|object[270]	new|new[270]	_	_
30-57	5672-5678	mucosa	object[270]	new[270]	_	_
30-58	5679-5682	and	_	_	_	_
30-59	5683-5692	low-grade	abstract[272]	giv[272]	_	_
30-60	5693-5700	chronic	abstract|abstract[272]	new|giv[272]	_	_
30-61	5701-5713	inflammation	abstract[272]	giv[272]	_	_
30-62	5714-5715	,	_	_	_	_
30-63	5716-5719	may	_	_	_	_
30-64	5720-5730	contribute	_	_	_	_
30-65	5731-5733	to	_	_	_	_
30-66	5734-5737	the	abstract[273]	giv[273]	_	_
30-67	5738-5743	onset	abstract[273]	giv[273]	_	_
30-68	5744-5747	and	_	_	_	_
30-69	5748-5759	progression	abstract[274]	new[274]	_	_
30-70	5760-5762	of	abstract[274]	new[274]	_	_
30-71	5763-5765	OA	abstract[274]|abstract[275]	new[274]|giv[275]	_	_
30-72	5766-5768	in	abstract[274]|abstract[275]	new[274]|giv[275]	_	_
30-73	5769-5774	obese	abstract[274]|abstract[275]|person[276]	new[274]|giv[275]|giv[276]	_	_
30-74	5775-5783	patients	abstract[274]|abstract[275]|person[276]	new[274]|giv[275]|giv[276]	_	_
30-75	5784-5785	.	_	_	_	_
